BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has BerGenBio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BGBIO is more volatile than 75% of Norwegian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: BGBIO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
7 Day Return
1 Year Return
Return vs Industry: BGBIO underperformed the Norwegian Biotechs industry which returned 121.8% over the past year.
Return vs Market: BGBIO underperformed the Norwegian Market which returned 35.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BerGenBio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDo Institutions Own BerGenBio ASA (OB:BGBIO) Shares?
3 months ago | Simply Wall StIt's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year
4 months ago | Simply Wall StWe're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow
Is BerGenBio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BGBIO (NOK25.74) is trading above our estimate of fair value (NOK4.16)
Significantly Below Fair Value: BGBIO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BGBIO is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: BGBIO is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BGBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BGBIO is good value based on its PB Ratio (3.8x) compared to the NO Biotechs industry average (5.5x).
How is BerGenBio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BGBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BGBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BGBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BGBIO's revenue (49.2% per year) is forecast to grow faster than the Norwegian market (4.2% per year).
High Growth Revenue: BGBIO's revenue (49.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BGBIO's Return on Equity is forecast to be high in 3 years time
How has BerGenBio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BGBIO is currently unprofitable.
Growing Profit Margin: BGBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BGBIO is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.
Accelerating Growth: Unable to compare BGBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (18.9%).
Return on Equity
High ROE: BGBIO has a negative Return on Equity (-48.34%), as it is currently unprofitable.
How is BerGenBio's financial position?
Financial Position Analysis
Short Term Liabilities: BGBIO's short term assets (NOK671.0M) exceed its short term liabilities (NOK72.6M).
Long Term Liabilities: BGBIO's short term assets (NOK671.0M) exceed its long term liabilities (NOK1.3M).
Debt to Equity History and Analysis
Debt Level: BGBIO is debt free.
Reducing Debt: BGBIO had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BGBIO has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 18.6% each year.
What is BerGenBio current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BGBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BGBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BGBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BGBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BGBIO's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Richard Godfrey, MPHARMS, MBA has been the Chief Executive Officer at BergenBio ASA since 2008. Mr. Godfrey is a Venture Partner of Sarsia Venture Management AS. He served as Chief Executive Officer of...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD564.45K) is about average for companies of similar size in the Norwegian market ($USD475.20K).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
Experienced Management: BGBIO's management team is considered experienced (2.4 years average tenure).
Experienced Board: BGBIO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BerGenBio ASA's company bio, employee growth, exchange listings and data sources
- Name: BerGenBio ASA
- Ticker: BGBIO
- Exchange: OB
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr2.262b
- Shares outstanding: 87.89m
- Website: https://www.bergenbio.com
Number of Employees
- BerGenBio ASA
- Jonas Lies vei 91
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-availabl...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/12 16:23|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.